Relationships between cytochrome b561 expressions and survival prognosis in breast cancer patients
Objective To investigate the expression levels and prognostic value of cytochrome b synthase(CYB)561 in breast cancer.Methods The expression level of CYB561 was compared between 76 patients with breast cancer and 40 patients with benign breast disease by immunohistochemistry.The Kaplan-Meier method was used to estimate the survival and log-rank test was performed.Determinants of survival prognosis of breast cancer were explored via COX regression analysis.Results The results of immunohistochemical scoring showed that the expression level of CYB561 was higher in breast cancer tissues than in normal ones(t=7.33,P=0.005),and in patients with pathological grade Ⅲ breast cancer than in those who pathological grades Ⅰ-Ⅱ(t=12.32,P＜0.001).The difference in expression levels of CYB561 in the four breast cancer subtypes subjected to ANOVA between the four groups was statistically significant(F=229.247,P＜0.001).Multiple comparisons showed that CYB561 expression levels were elevated in TNBC patients compared with Luminal A,Luminal B and HER2-positive patients(t=14.054,15.899,12.538,all P＜0.001).In addition,the difference in CYB561 expression levels in estrogen receptor and progesterone receptor status was statistically significant(t=7.54,2.51,both P＜0.001).The results of Kaplan-Meier survival analyses showed that patients in the CYB561 high-expression group showed shorter 5-year overall survival and 5-year disease-free survival than those in the CYB561 low expression group[(41.09±1.50)months vs(52.56±1.74)months,(25.39±1.99)months vs(33.42±2.34)months,(χ2=7.780,5.219,P=0.005,0.022)].The results of COX regression analyses showed that the expression level of CYB561(HR=0.244,95%CI=0.085～0.697,P=0.008)could make a difference to the survival prognosis of breast cancer patients.Conclusion CYB561 may play an important role in the development of breast cancer,and its expression level can be used as a potential biomarker for prognosis evaluation and diagnosis of breast cancer patients.
万方数据
维普
